{"product_id":"precision-cancer-therapies-targeting-oncogenic-drivers-and-signaling-pathways-in-lymphoid-malignancies-9781119819929","title":"Precision Cancer Therapies Targeting Oncogenic","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eTargeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies\u003c\/b\u003e \u003cp\u003e\u003cb\u003eA thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eTargeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice\u003c\/i\u003e focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. \u003c\/p\u003e\u003cp\u003eThe work primarily focuses on how to understand and translate fundamental principles of basic science into informati\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eList of Contributors xix\u003c\/p\u003e \u003cp\u003eVolume Foreword xxiv\u003c\/p\u003e \u003cp\u003eVolume Preface xxvi\u003c\/p\u003e \u003cp\u003eSeries Preface xxviii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I Biological Basis of the Lymphoid Malignancies 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Fundamental Principles of Lymphomagenesis 3\u003cbr\u003ePierre Sujobert, Philippe Gaulard, and Laurence de Leval\u003c\/p\u003e \u003cp\u003e2 Identifying Molecular Drivers of Lymphomagenesis 12\u003cbr\u003eJennifer Shingleton and Sandeep S. Dave\u003c\/p\u003e \u003cp\u003e3 Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies 25\u003cbr\u003eSean Harrop, Michael Dickinson, Ricky Johnstone, and Henry Miles Prince\u003c\/p\u003e \u003cp\u003e4 Animal Models of Lymphoid Malignancies 40\u003cbr\u003eAnjali Mishra\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II Targeting the PI3 Kinase-AKT-mTOR Pathway 53\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5 Principles of PI3K Biology and Its Role in Lymphoma 55\u003cbr\u003e\u003ci\u003eRalitsa R. Madsen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Pharmacologic Differentiation of Drugs Targeting the PI3K-AKT-mTOR Signaling Pathway 71\u003cbr\u003e\u003ci\u003eInhye E. Ahn, Jennifer R. Brown, and Matthew S. Davids\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Clinical Experience with Phosphatidylinositol 3-Kinase Inhibitors in Hematologic Malignancies 86\u003cbr\u003e\u003ci\u003eAlessandro Broccoli and Pier Luigi Zinzani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 PI3 Kinase, AKT, and mTOR Inhibitors 113\u003cbr\u003e\u003ci\u003eJoel McCay and John G. Gribben\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III Targeting Programmed Cell Death 131\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology 133\u003cbr\u003e\u003ci\u003eSarah T. Diepstraten, John E. La Marca, David C.S. Huang, and Gemma L. Kelly\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Pharmacologic Features of Drugs Targeting BCL2 Family Members 151\u003cbr\u003e\u003ci\u003eJennifer K. Lue and Owen A. O’Connor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Clinical Experience with Pro-Apoptotic Agents 165\u003cbr\u003e\u003ci\u003eThomas E. Lew and John F. Seymour\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Promising Combinations of Drugs Targeting Apoptosis 186\u003cbr\u003e\u003ci\u003eWilliam G. Wierda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV Targeting the Cancer Epigenome 197\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 The Role of Epigenetic Dysregulation in Lymphoma Biology 199\u003cbr\u003e\u003ci\u003eQing Deng and Michael R. Green\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Quantitating and Characterizing the Effects of Epigenetic Targeted Drugs 209\u003cbr\u003e\u003ci\u003eEmily Gruber, Alexander C. Lewis, and Lev M. Kats\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Clinical Experience with Epigenetic Drugs in Lymphoid Malignancies 225\u003cbr\u003e\u003ci\u003eEnrica Marchi, Ipsita Pal, and John Sanil Manavalan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Future Prospects for Targeting the Epigenome in Lymphomas 236\u003cbr\u003e\u003ci\u003eYusuke Isshiki and Ari Melnick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection V Targeting the B-cell Receptor (BCR) 249\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18 The Pathologic Role of BCR Dysregulation in Lymphoid Malignancies 251\u003cbr\u003e\u003ci\u003eJan A. Burger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Pharmacologic Features of Drugs Targeting Bruton’s Tyrosine Kinase (BTK) 268\u003cbr\u003e\u003ci\u003eJoel McCay and John G. Gribben\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Clinical Experience with Drugs Targeting Bruton’s Tyrosine Kinase (BTK) 278\u003cbr\u003e\u003ci\u003eJulia Aronson, Anthony R. Mato, Catherine C. Coombs, Prioty Islam, Lindsey E. Roeker, and Toby Eyre\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Promising Combinations of BTK Inhibitors with Other Targeted Agents 287\u003cbr\u003e\u003ci\u003eNicholas J. Schmidt, Michael E. Williams, and Craig A. Portell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VI Protein Degraders and Membrane Transport Inhibitors 301\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22 The Biological Basis for Targeting Protein Turnover in Malignant Cells 303\u003cbr\u003e\u003ci\u003eRobert Z. Orlowski\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Preclinical Overview of Drugs Affecting Protein Turnover in Multiple Myeloma 313\u003cbr\u003e\u003ci\u003eGiada Bianchi, Matthew Ho, and Kenneth C. Anderson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Clinical Experience on Proteasome Inhibitors in Cancer 331\u003cbr\u003e\u003ci\u003eNoa Biran, Pooja Phull, and Andre Goy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Targeting Nuclear Protein Transport with XPO Inhibitors in Lymphoma 361\u003cbr\u003e\u003ci\u003eFarheen Manji, Kyla Trkulja, Rob C. Laister, and John Kuruvilla\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Heterobifunctional Degraders for the Treatment of Lymphoid Malignancies 372\u003cbr\u003e\u003ci\u003eAshwin Gollerkeri, Jared Gollob, and Nello Mainolfi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VII Novel Targets and Therapeutic Prospects in Development 381\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 Strategies for Targeting the JAK-STAT Pathway in Lymphoid Malignancies 383\u003cbr\u003e\u003ci\u003eDavid J. Feith, Johnson Ung, Omar Elghawy, Peibin Yue, James Turkson, and Thomas P. Loughran Jr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Strategies for Targeting MYC 402\u003cbr\u003e\u003ci\u003eJemma Longley and Andrew Davies\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Targeting NOTCH in Lymphoid Malignancies 411\u003cbr\u003e\u003ci\u003eDeborah Piffaretti, Georgia Alice Galimberti, and Davide Rossi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Targeting NF-κB in Oncology, an Untapped Therapeutic Potential 428\u003cbr\u003e\u003ci\u003eMatko Kalac\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Targeting the Cell Cycle and Cyclin-dependent Kinases 444\u003cbr\u003e\u003ci\u003eChiara Tarantelli and Francesco Bertoni\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eReferences 452\u003c\/p\u003e \u003cp\u003eIndex 457\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49407162515799,"sku":"9781119819929","price":135.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119819929.jpg?v=1730498391","url":"https:\/\/bookcurl.com\/products\/precision-cancer-therapies-targeting-oncogenic-drivers-and-signaling-pathways-in-lymphoid-malignancies-9781119819929","provider":"Book Curl","version":"1.0","type":"link"}